SBC Medical Group (NASDAQ:SBC) Issues Earnings Results

SBC Medical Group (NASDAQ:SBC) posted its earnings results on Thursday. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02), FiscalAI reports. SBC Medical Group had a return on equity of 15.90% and a net margin of 24.09%.The business had revenue of $49.19 million for the quarter, compared to the consensus estimate of $45.37 million.

Here are the key takeaways from SBC Medical Group’s conference call:

• Positive Sentiment: SBC reported strong second-quarter results, with revenue up 13% to $49 million, adjusted EBITDA up 32% to $20 million, and a 41% margin. Clinic locations increased to 287, visits rose 10%, and average spend per visit increased 9%.
• Positive Sentiment: Management said domestic aesthetic medicine has re-accelerated after marketing, pricing, and treatment reforms, with same-clinic revenue up 6% and first-half transaction value up 19%. It expects a more favorable competitive environment as the pace of new clinic openings slows.
• Positive Sentiment: AI is being deployed across customer service, marketing, call-center operations, site selection, and employee training, with management targeting higher clinic revenue and greater operating efficiency. Planned service-fee increases are expected to add roughly JPY 15 million annually, with most of the contribution flowing to profit.
• Positive Sentiment: The company is broadening beyond aesthetics through non-aesthetic healthcare, international expansion, and new longevity offerings. It is targeting 1,000 clinics by 2035, while pursuing asset-light expansion in Southeast Asia and further growth with OrangeTwist in the U.S.
• Negative Sentiment: A weaker Japanese yen remains a headwind because most operations are yen-denominated, while competition in Japan has recently been intense. SG&A also increased, although management attributed much of the rise to one-time costs related to the secondary offering.

SBC Medical Group Trading Up 8.8%

Shares of NASDAQ SBC traded up $0.28 during midday trading on Friday, reaching $3.47. The stock had a trading volume of 135,047 shares, compared to its average volume of 90,019. The firm has a market cap of $356.06 million, a price-to-earnings ratio of 8.90 and a beta of 0.59. The company’s 50 day moving average price is $3.07 and its 200 day moving average price is $3.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.78 and a current ratio of 3.82. SBC Medical Group has a twelve month low of $2.78 and a twelve month high of $5.07.

Key SBC Medical Group News

Here are the key news stories impacting SBC Medical Group this week:

• Positive Sentiment: Second-quarter revenue increased 13% year over year to $49.19 million, exceeding analysts’ $45.37 million estimate. Net income surged 335%, while adjusted EBITDA rose 32%, suggesting that the company’s completed restructuring is supporting renewed growth. SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results
• Positive Sentiment: SBC outlined a long-term goal of reaching 1,000 clinics by 2035 and identified potential annual fee revenue of approximately $15 million, providing investors with a larger growth opportunity if the expansion plan is achieved. SBC targets 1,000 clinics by 2035 while outlining $15M annual fee upside
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and maintained an $8 price target, well above the recent trading level. The endorsement may reinforce the bullish case among investors. BTIG Research rating update
• Neutral Sentiment: Management’s earnings call emphasized restructuring completion and accelerating growth, but investors will likely look for evidence that the clinic expansion strategy can translate into sustained cash flow and earnings growth. SBC Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted earnings were $0.10 per share, below the $0.12 consensus estimate. The miss could limit enthusiasm despite the stronger-than-expected revenue and profitability figures. SBC Medical Group second-quarter financial results

Institutional Trading of SBC Medical Group

Several large investors have recently modified their holdings of SBC. Russell Investments Group Ltd. lifted its position in shares of SBC Medical Group by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock valued at $51,000 after acquiring an additional 8,771 shares during the period. Barclays PLC boosted its stake in SBC Medical Group by 123.7% during the fourth quarter. Barclays PLC now owns 17,779 shares of the company’s stock worth $77,000 after acquiring an additional 9,831 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in SBC Medical Group by 91.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 27,341 shares of the company’s stock worth $118,000 after purchasing an additional 13,074 shares during the period. Wells Fargo & Company MN grew its holdings in SBC Medical Group by 195.1% in the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock worth $54,000 after purchasing an additional 8,348 shares during the period. Finally, Nuveen LLC bought a new stake in SBC Medical Group in the fourth quarter valued at $53,000. Institutional investors and hedge funds own 60.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SBC Medical Group in a report on Thursday. Weiss Ratings lowered SBC Medical Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 22nd. Finally, Wall Street Zen raised SBC Medical Group to a “hold” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.50.

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.